Zydus Lifesciences Gains USFDA Clearance for Injectables Facility

Zydus Lifesciences (

) announced that its USFDA pre-approval inspection at the Unit-9 injectables facility in Ahmedabad's Zydus Biotech Park, Changodar, concluded without observations. The inspection occurred from February 16 to 19, 2026, signaling strong regulatory compliance in a high-scrutiny segment. This zero-observation outcome bolsters prospects for US market product launches, where injectables approvals hinge on such validations. Recent developments include USFDA final approval for bosentan tablets treating pulmonary arterial hypertension and the ANYRA eye care launch. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.